PubMed Trending Research Digest — September 25, 2026

Automated digest · 96 articles · 14 research areas · September 25, 2026

Overview

This week’s digest is dominated by two converging trends: (1) precision risk and treatment selection using better models and real-world evidence, and (2) mechanistic biology that turns into actionable therapeutic vulnerabilities. On the clinical side, studies extend and refine treatment windows and intensity—such as adding IV tenecteplase before thrombectomy for basilar artery occlusion and clarifying anticoagulation intensity in hospitalized COVID-19—while other work uses registries, target-trial emulation, and network meta-analyses to compare strategies (e.g., LAAO vs DOACs, infliximab vs vedolizumab, renal outcomes with SGLT2 vs GLP-1 agents). Risk stratification also shows up in prevention and counseling: residual ovarian cancer risk modeling for BRCA1/2 carriers, thrombotic risk quantification for menopausal hormone therapy, and biomarker approaches for cardiometabolic multimorbidity.

On the mechanistic front, multiple articles converge on regulated cell death and stress-response pathways. Ferroptosis/cuproptosis biology is advanced by both reviews and primary studies (e.g., ecDNA vulnerabilities via MMEJ, PDAC protection from ferroptosis via RTM-delivered selenium, and new metabolic regulators such as lactate-driven necroptosis). In parallel, mTOR–translation coupling and aging frameworks continue to provide testable targets, from Drosophila nutrient–translation control to mTORC1-driven astrocyte reactivity in TSC. Immunology is equally prominent: studies dissect IL-4-rich vs GC-independent IgE memory recall, define tolerogenic T-cell populations in liver transplantation, and map how macrophage or fibroblast subsets tune inflammation.

Finally, translational infectious-disease and neurobiology threads run through the set. Structural and genomic work (malaria invasion complexes, alphavirus-neutralizing constructs, ASFV transcription mapping, Leishmania trans-splicing machinery) supports next-generation countermeasures, while neuro-focused atlases and gut–brain/microbiome studies (epilepsy, Alzheimer’s monitoring, glymphatic AQP4 organization) aim to connect cellular states to symptoms and treatment response. Together, the week highlights a pipeline from systems-level measurement (biomarkers, atlases, real-world outcomes) to pathway-level interventions (cell death, mTOR, immune checkpoints, metabolic vulnerabilities).

---

Neurobiology & brain structure/function (epilepsy gut-brain, glymphatic/AQP4, brain atlases, ASD/TH signaling, lipidome mapping)

The microbiota-gut-brain axis in epilepsy: Mechanistic insights and emerging probiotic-based therapeutics.

This review examined the gut–brain axis in epilepsy, focusing on how gut dysbiosis (e.g., reduced Lactobacillus, Bifidobacterium, and Faecalibacterium) may contribute to seizure pathophysiology and how probiotic-based therapies could modify these mechanisms in people with epilepsy. It synthesizes evidence that gut microbiota can influence brain function via immune signaling, neurotransmitter availability, and gut-brain barrier integrity, potentially contributing to pharmacoresistance. These mechanistic insights support emerging probiotic/ microbiome-targeted strategies as potential adjuncts to conventional antiepileptic therapy, particularly for patients with drug-resistant epilepsy.

Matta T, Bishnoi M, Chopra K et al. · International review of neurobiology · (2026) · View on PubMed ↗

Dynamic changes in plasma biomarkers of Alzheimer’s disease in patients treated with lecanemab: a longitudinal cohort study.

This longitudinal cohort study analyzed 130 plasma proteins in patients with early symptomatic Alzheimer’s disease who were amyloid-biomarker positive and treated with biweekly lecanemab infusions, assessing associations with conversion to amyloid PET negativity and cognitive change. The key finding was that plasma biomarker dynamics track neurodegeneration-related processes during anti-amyloid therapy and relate to amyloid PET status conversion and cognition (specific proteins/associations are not visible due to truncation). These results could enable less invasive monitoring of treatment response and disease progression in lecanemab-treated patients.

Mu R, Hofmann A, Gong K et al. · The Lancet. Neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Predictors of trajectories of suicidal thoughts in Texas youth depression and suicide research network youth.

This study analyzed trajectories of suicidal thoughts in Texas youth with depression/suicidality using longitudinal self-reported data (n=1,449) and group mixture models, then applied random forest analyses to identify baseline predictors of trajectory membership. The key finding was identification of distinct suicidal-ideation trajectory groups over follow-up and baseline clinical/sociodemographic features that predict which trajectory youth follow (specific predictors are truncated). Scientifically and clinically, this supports risk stratification approaches that could target monitoring and interventions to youth most likely to experience worsening suicidal thoughts.

Minhajuddin A, Walker RA, Jha MK et al. · Psychological medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Cannabis use is associated with increased risk of violence: A systematic review and meta-analysis.

This systematic review and meta-analysis synthesized evidence from 63 peer-reviewed studies (N=265,079) on cannabis use and violence, considering cannabis users as perpetrators and/or victims across general and psychiatric populations. Random-effects models found cannabis users had a significantly higher risk of perpetrating violent acts, with the association also reported in psychiatric patients. These findings strengthen the evidence base for cannabis as a modifiable risk factor for violence and support targeted prevention and risk assessment in clinical settings.

Trotta G, Rodriguez V, Marino P et al. · Psychological medicine · (2026) · View on PubMed ↗ · Free PDF ↗

AI-based characterization of Alzheimer’s disease phenotypes from population-scale single-cell data.

This study used the PsychAD project’s population-scale single-nucleus RNA sequencing dataset (over 6 million nuclei from >1,000 prefrontal cortex brains) to develop an AI framework, PASCode, for scoring single-cell phenotype associations in Alzheimer’s disease. The model identified approximately 1.5 million phenotype-associated cells from 584 donors with Alzheimer’s disease, linking cellular states to clinical phenotype variation. This provides a scalable computational route to connect AD molecular heterogeneity to symptoms, supporting more precise phenotype stratification and hypothesis generation.

He C, Li AZ, Hanthanan Arachchilage K et al. · Nature medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Single-cell atlas of transcriptomic vulnerability across brain disorders.

This work generated a population-scale single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex using specimens from 1,494 donors (over 6.3 million nuclei) spanning neurotypical controls and eight brain disorders including Alzheimer’s disease and diffuse Lewy body disease. The atlas maps disease-associated cellular programs and “transcriptomic vulnerability” across disorders, enabling cross-disease comparisons at cell-type resolution. Scientifically, it offers a resource for identifying shared and disorder-specific molecular mechanisms that could guide targeted biomarker discovery and therapeutic development.

Lee D, Koutrouli M, Masse NY et al. · Nature · (2026) · 5 citations · View on PubMed ↗ · Free PDF ↗

Lifespan single-cell transcriptomic atlas of the human prefrontal cortex.

This study created a lifespan single-cell transcriptomic atlas of the human prefrontal cortex to characterize how cellular programs change from early development through late adulthood. By profiling dorsolateral prefrontal cortex cell states across ages (details truncated in the abstract), it aimed to define age-related molecular trajectories that may underlie differential vulnerability to psychiatric and neurodegenerative disease. The atlas provides a reference framework for interpreting how normal aging shapes disease risk and for identifying age-dependent therapeutic windows.

Yang H, Clarence T, Scott MR et al. · Nature · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Structural basis of step II spliced leader RNA trans-splicing in trypanosomatid parasites.

The study investigated the structural and mechanistic basis of step II spliced leader (SL) RNA trans-splicing in the kinetoplastid parasite Leishmania tarentolae. Using cryogenic electron microscopy, the authors resolved step II SL trans-splicing machineries and revealed how the SL exon is ligated to the 5′ end of target mRNAs. These structures provide a molecular framework for understanding a core mRNA biogenesis pathway in Trypanosoma/Leishmania and may enable future therapeutic targeting of SL trans-splicing.

Nadenoen T, Biglione FA, Vandevenne M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis.

The study investigated whether mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis complex (TSC) using human brain organoid models. The authors showed that activating mTORC1 in TSC-mutant neural lineages promotes astrocyte reactivity even in the absence of seizures, separating glial effects from seizure-driven secondary changes. This supports a direct, gene-driven role for mTORC1 in astrocyte pathology in TSC and strengthens the rationale for targeting mTORC1/glial pathways to treat cortical tubers and epilepsy.

Li TL, Blair JD, Yoo T et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

The lipidomic architecture of the mouse brain.

The study mapped the spatial organization of the adult mouse brain lipidome across sexes and during pregnancy to define how membrane lipids relate to brain function. Using micrometric-scale lipid mapping, the authors generated a lipid atlas showing that lipids form fine-grained “lipizones” that align with functional anatomy and exhibit membrane-lipid spatial heterogeneity. This provides a high-resolution biochemical map that can guide mechanistic studies of lipid dysregulation in neurological disease.

Fusar Bassini L, Schede HH, Capolupo L et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Revisiting Culture Conditions of Satellite Cells In Vitro for Skeletal Muscle Regeneration and Therapeutic Applications.

This article reviewed and re-evaluated in vitro culture conditions for satellite cells (SCs) used for skeletal muscle regeneration and therapeutic applications, with emphasis on how SC activation, proliferation, differentiation, and maturation depend on culture parameters. The key finding was that optimizing culture conditions is critical to preserve physiologic SC behavior and improve translational relevance for therapies, including contexts such as Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. Scientifically, the review supports more standardized and effective SC culture protocols to enhance regenerative outcomes in cell-based muscle therapies.

Kumari P, Raval A, Rana P et al. · Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft · (2026) · View on PubMed ↗

Spatial organization of AQP4 water channel expression in the human brain.

This study mapped the spatial organization of aquaporin-4 (AQP4) water channel expression across the human brain and related it to glymphatic clearance and vascular physiology. By reconstructing whole-brain glymphatic-related topography from AQP4 gene expression, the authors found AQP4 expression is highly structured, peaking in subcortical, ventral, and periventricular regions near cerebrospinal fluid reservoirs and perivascular interfaces. The resulting AQP4–vascular–disease framework helps explain regional vulnerability in glioma and neurodegenerative disorders and supports glymphatic-targeted hypotheses.

Taheri T, Farahani A, Liu ZQ et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

An ASXL3-thyroid hormone axis in parvalbumin interneurons controls autism-like behaviors.

The study investigated how ASXL3 haploinsufficiency in mice alters cortical development and parvalbumin (PV) interneuron circuitry to produce autism-like behaviors, and whether thyroid hormone (TH) signaling is causally involved. It found that Asxl3 loss derepresses the TH-inactivating enzyme DIO3 via altered histone H2A monoubiquitination, depleting brain TH, and that conditional deletion of the TH receptor Thra in inhibitory neuron progenitors phenocopies PV interneuron expansion and related behavioral abnormalities. This links an ASXL3–DIO3–THRA pathway to PV circuit remodeling, highlighting TH signaling as a potential mechanistic and therapeutic entry point for ASXL3-associated ASD.

Ding C, Yuan Y, Hu Y et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

A push-pull gut-brain signal regulates flexible learning in Caenorhabditis elegans.

The study examined how a gut-to-brain neuropeptide signaling pathway regulates flexible learning in Caenorhabditis elegans during exposure to the pathogen Pseudomonas aeruginosa (PA14), focusing on the FLP-18 neuropeptide and its receptors in ADF sensory neurons. It found that PA14 upregulates intestinal FLP-18, which acts on antagonistic receptors NPR-5 and NPR-6 to accelerate versus dampen ADF activity, thereby shaping learning-curve dynamics according to pathogen virulence and internal physiological state. This provides a mechanistic model for how internal state and gut signals tune learning strategies, informing broader principles of adaptive behavior.

Liu H, Sun Y, Jiang C et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neonatal outcomes & microbiome interventions (probiotics, FMT/IBS, gut-brain microbiome in epilepsy)

Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial.

This phase 3 randomized, double-blind, placebo-controlled trial studied faecal microbiota transplantation (FMT) in men and women aged 18–65 years with moderate-to-severe irritable bowel syndrome (IBS) diagnosed by Rome IV criteria and IBS-SSS ≥175 at five hospitals in Norway. The key finding was the efficacy and safety outcome of FMT versus placebo for improving IBS symptoms and tolerability over the trial period (details truncated in the provided abstract). If FMT shows clinically meaningful benefit with acceptable safety, it would provide a microbiota-restoring disease-modifying option for IBS beyond standard pharmacologic symptom control.

Johnsen PH, Juul FE, Hoff DAL et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

Probiotics and Risk of Death, Necrotizing Enterocolitis, and Sepsis in Very Preterm Infants.

Using the Swedish Neonatal Quality Register, this population-based cohort study assessed whether probiotic supplementation in very preterm infants (28+0 to 31+6 weeks’ gestation) was associated with death, necrotizing enterocolitis (NEC), and/or culture-proven sepsis. The study quantified associations between probiotic exposure and these clinically important outcomes in a national real-world setting. The evidence helps determine whether routine probiotic use for very preterm infants reduces major morbidity and mortality.

Mitha A, Söderquist Kruth S, Sinervo E et al. · JAMA network open · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

---

Cell death mechanisms & ferroptosis/cuproptosis (including metabolic regulation of necroptosis)

Resident tissue macrophages transfer selenium transporter protein to protect pancreatic cancer from ferroptosis.

This study investigated how resident tissue macrophages (RTMs) protect pancreatic ductal adenocarcinoma (PDAC) from ferroptosis by transferring the selenium transporter Selenop to tumor cells, using single-cell profiling, spatial analysis, lineage tracing, RTM depletion, and selenium tracing. It found that RTMs localize to the tumor border and promote EMT, growth, and metastasis by LRP8-dependent uptake of Selenop by EMT-high tumor cells, increasing tumor-cell selenium and thereby suppressing ferroptosis. Scientifically, it identifies an RTM–Selenop–LRP8 axis as a vulnerability in PDAC that could be therapeutically targeted to enhance ferroptosis-based tumor control.

Guo W, Li Z, Chen Q et al. · Cell · (2026) · View on PubMed ↗

Mammals produce cyclo-octasulfur to suppress lipid peroxidation and ferroptosis.

This study investigated a newly identified sulfur metabolite pathway in mammals, showing that cyclo-octasulfur (S8) accumulates in mitochondrial membranes and lipid droplets in mouse and human cells and suppresses ferroptosis. It found that lipid droplet-associated nitric oxide synthase contributes to S8 biosynthesis and that S8 limits lipid peroxidation, thereby suppressing ferroptosis, with supportive evidence from an intra-articular S8 injection mouse model of osteoarthritis (details truncated). These findings suggest S8 or its biosynthetic pathway as a potential therapeutic strategy to prevent ferroptosis-driven tissue damage.

Barayeu U, Ogata S, Takata T et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.

This review article summarized the signaling pathways, disease associations, and therapeutic targets for cuproptosis and ferroptosis, two metal-dependent regulated cell death programs. It highlighted that cuproptosis is triggered by copper-mediated disruption and aggregation of lipoylated mitochondrial proteins, whereas ferroptosis is driven by iron-dependent lipid peroxidation, with both intersecting through mitochondrial metabolism, redox imbalance, and organelle crosstalk. The synthesis provides a framework for developing therapies that selectively modulate these death pathways in cancer and other diseases.

Li YY, Tay FR · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Iron and the lung: emerging roles of iron metabolism in pulmonary disease pathogenesis and therapy.

This review summarized emerging roles of iron metabolism in pulmonary disease pathogenesis and therapy, focusing on lung iron homeostasis regulators including transferrin, ferritin, ferroportin, hepcidin, and the iron responsive element/iron regulatory protein system. The key finding was that dysregulation of these iron-handling pathways contributes to multiple lung diseases through iron-dependent oxidative injury and altered immune and cellular responses. The review is significant because it frames iron metabolism as a potential therapeutic target across conditions such as COPD, asthma, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and infectious lung diseases.

Galaris A, Toumpanakis D, Galaris D et al. · European respiratory review : an official journal of the European Respiratory Society · (2026) · View on PubMed ↗ · Free PDF ↗

Lactate couples metabolic state to necroptosis across pathological and physiological conditions.

This Cell Metabolism study investigated how lactate regulates necroptosis by identifying a direct biochemical mechanism across pathological and physiological contexts. It showed that lactate promotes necroptosis via PCAF-mediated K63 lactylation of RIPK3, enhancing RIPK3 kinase activity and stabilizing the RIPK3–MLKL complex, with suppression by RIPK3 K63R mutation or PCAF loss. The mechanism links metabolic state to cell-death decision-making and suggests potential therapeutic targets (LDH inhibition, PCAF, or RIPK3 lactylation) for necroptosis-driven diseases.

Zhang N, Huang X, Lu S et al. · Cell metabolism · (2026) · View on PubMed ↗

---

Molecular oncology mechanisms & targeted resistance (DNA repair, ecDNA, mTOR resistance, CAR-T/BCMA, gene therapy, kinase inhibitors)

Ceramide synthesis mediates colorectal cancer metastasis through a YAP-driven regenerative program.

This study examined how colorectal cancer metastasis is driven by tumor-intrinsic ceramide metabolism, including the role of the enzyme dihydroceramide desaturase Degs1 and downstream YAP signaling, using dietary fat exposure and mechanistic pathway experiments in colorectal cancer models. It found that dietary fat increases de novo ceramide biosynthesis via Degs1, leading to ceramide accumulation that activates YAP through PP2A-mediated dephosphorylation and induces a YAP-driven regenerative program (including Basp1) that promotes metastasis. Clinically, targeting ceramide synthesis (e.g., Degs1) or the YAP/PP2A axis could reduce metastatic progression in colorectal cancer.

Goswami S, Zhang Q, Yildiz AB et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.

This study used a human induced pluripotent stem cell (iPSC)-based multidimensional drug discovery pipeline to identify CGS15943 (CGS) as a candidate therapy for cardiac fibrosis and then tested it in human cardiac fibroblasts, engineered heart tissues, and animal models of heart failure. It found that CGS acts through an atypical adenosine receptor (AR)-dependent signaling pathway that converges on Gβγ (with downstream antifibrotic effects) (mechanistic details truncated). If validated clinically, CGS represents a potential first-in-class approach to directly target fibrotic remodeling in heart failure rather than only treating symptoms.

Zhang H, Shivnaraine RV, Ren L et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

This Center for International Blood and Marrow Transplant Research registry analysis evaluated real-world outcomes of frail versus nonfrail patients with relapsed/refractory multiple myeloma treated with the anti-BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel) between March 2022 and December 2023. Frailty (defined using an adapted simplified score incorporating age, performance status, and comorbidities) was present in 33.8% of 541 patients with available status, and overall response rates were comparable between frail (82.8%) and nonfrail (88.5%) groups. The results suggest cilta-cel can be effective in frail patients in routine practice, informing treatment selection and counseling for a high-risk subgroup.

Mian H, Faisal MS, Chen T et al. · Cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Abasic site repair in APE1-deficient mouse embryonic stem cells: a matter for the MRN complex and ATM signaling.

This study used APE1-deficient mouse embryonic stem cells with inducible depletion of thymine DNA glycosylase (TDG) to dissect how abasic (AP) sites arise during base excision repair (BER) versus active DNA demethylation. TDG activity accounted for a substantial fraction of AP sites in these cells, directly linking active DNA demethylation to AP site formation and clarifying lesion sources in APE1-deficient BER contexts. Scientifically, it refines the mechanistic understanding of how BER intersects with epigenetic reprogramming, which is relevant to genome stability and demethylation-associated DNA damage.

Hrovat AM, Noreen F, Schwarz SD et al. · Nucleic acids research · (2026) · View on PubMed ↗ · Free PDF ↗

A design approach for bitopic kinase inhibitors.

The study developed and tested a design framework for bitopic kinase inhibitors using ABL1 and EGFR as model targets. By systematically varying ligand choice, linkage vector, and linker length, the authors showed that bitopic potency depends on inter-ligand cooperativity and linker entropy, and they applied the approach to address resistance constraints in ABL1 inhibitors used for BCR::ABL1-driven leukemia. This provides actionable principles for designing more potent and selective kinase inhibitors that can better overcome resistance.

Stevenson JW, Lou K, Reynolds JA et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Hepatocytes promote liver metastasis of pancreatic cancer by providing serine.

The study investigated how hepatocytes influence liver metastasis of pancreatic ductal adenocarcinoma (PDAC), focusing on metabolic support via serine. The authors reported that hepatocytes promote metastatic colonization of PDAC cells by providing serine, particularly benefiting PHGDH-deficient tumor cells that rely on exogenous serine. This identifies a tumor–liver metabolic coupling that could be exploited therapeutically by targeting serine availability or PHGDH/exSer dependencies.

Ganguly K, Yamamoto K, Rodencal J et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

The mutational dynamics of the Arabidopsis centromeres.

The study examined the mutational dynamics of Arabidopsis thaliana centromeres using replicated genome assemblies from mutation accumulation lines. The authors found that centromere-specific indels frequently occur in kilobase-sized events that preserve tandem-repeat arrays by adding or removing complete repeat units, while point mutations accumulate at an ~10-fold higher rate than elsewhere in the genome. These results clarify how centromere repeat structure is maintained despite ongoing mutation, informing models of centromere evolution and genome stability.

Dong X, Jiao WB, Goldkuhle L et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

MMEJ repair of breaks at TA repeats maintains ecDNA and cancer fitness.

The study investigated how extrachromosomal DNA (ecDNA) is maintained in cancer cells, focusing on microhomology-mediated end joining (MMEJ) versus non-homologous end joining (NHEJ) and homologous recombination (HR). Inhibiting MMEJ selectively depleted ecDNA, caused ecDNA-specific damage, and promoted sequestration of ecDNA into micronuclei, reducing the fitness of ecDNA-dependent tumors. These findings identify MMEJ as a potential therapeutic vulnerability to impair oncogene-amplifying ecDNA and overcome ecDNA-driven aggressiveness and treatment resistance.

Billing D, Selvaraj M, Kelley ME et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.

The study investigated the mechanism of mTOR inhibitor resistance in clear cell renal cell carcinoma (ccRCC), focusing on SPOP-mediated ubiquitination of the histone modifier ZMYND8 and its effects on phase separation. SPOP (CULLIN3-RING E3 ligase) promoted K63-linked polyubiquitination of ZMYND8 at lysine 398, which prevented ZMYND8 phase separation, enabled ZMYND8–ZHX2 transactivation complex formation, and drove resistance to mTOR inhibitors such as everolimus and temsirolimus. This identifies a SPOP–ZMYND8 ubiquitination/phase-separation axis as a mechanistic driver and potential biomarker/target for overcoming mTOR inhibitor resistance in ccRCC.

Tang B, Sun R, Shao J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial.

This phase 3 multicentre randomized, double-blind, placebo-controlled trial tested whether adjuvant aspirin improves disease-free survival after curative-intent treatment of colorectal cancer liver metastases. Patients were assigned to aspirin versus placebo following curative-intent therapy, and the trial evaluated recurrence-related outcomes over follow-up. If effective, aspirin could become a low-cost adjuvant strategy to reduce recurrence after liver-metastasis treatment.

Yaqub S, Valberg M, Bjørnbeth BA et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

This study examined how CD4 T cells shape responses to KRAS inhibition in pancreatic ductal adenocarcinoma using mouse models of KRAS inhibitor response and relapse. It found that an IL-21 cytokine mimic (21h10) induced long-term, durable remissions that depended on Th1-polarized CD4 T cells rather than CD8 T cells. These results support a strategy of combining KRAS inhibition with IL-21/Th1 CD4 T-cell–directed immunotherapy to overcome relapse in PDAC.

Qiang L, Hoffman MT, Chun JH et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome.

This integrated analysis studied etuvetidigene autotemcel (etu-cel) gene therapy in patients with Wiskott-Aldrich syndrome caused by variants in the WAS gene. The therapy uses autologous hematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding WAS complementary DNA, evaluated across two prospective open-label studies (phase 1–2 with 8 participants and phase 3 with 10 participants) plus expanded access (9 participants). Clinically, it provides efficacy and safety evidence for a targeted gene-correction approach in a life-threatening X-linked immunodeficiency.

Ferrua F, Cenciarelli S, Giannelli S et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

This phase 1 study evaluated anito-cel (anito-cel), an autologous BCMA-directed CAR T cell therapy using a synthetic d-domain binder (ddBCMA), in patients with relapsed or refractory multiple myeloma. It assessed safety and efficacy at dose levels of 100×10^6 and 300×10^6 CAR+ T cells, with primary endpoints focused on treatment-period adverse events and establishing the recommended phase 2 dose in heavily pretreated or triple-class refractory patients. The significance is early clinical characterization of a next-generation BCMA CAR T design for improving outcomes in refractory myeloma.

Frigault MJ, Dhakal B, Jakubowiak AJ et al. · The New England journal of medicine · (2026) · 1 citations · View on PubMed ↗

Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.

This prespecified final 5-year follow-up analysis of the phase III ASCOT trial studied adjuvant oral S-1 (a fluoropyrimidine) versus observation after resection for biliary tract cancer (BTC) in a multicenter randomized trial in Japan. Among 440 patients, it reported 5-year overall survival of 64% with S-1 versus 52% with observation at a median follow-up of 61.5 months. The long-term results are clinically important for confirming durable survival benefit of adjuvant S-1 in resected BTC.

Ikeda M, Nakachi K, Konishi M et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002.

This study evaluated the BRAF inhibitor vemurafenib in children under 25 years with recurrent or progressive BRAFV600E-mutant brain tumors in the multicenter PNOC002 phase 0/1 trial. The trial established the recommended phase II dose (RP2D) and assessed preliminary efficacy using tumor growth trajectories and rebound criteria (≥25% increase in tumor size/volume). These results support targeted MAPK-pathway inhibition with vemurafenib as a precision therapy strategy for pediatric BRAFV600E-driven brain tumors and inform dosing for future phase II testing.

Nicolaides T, Hoogendijk R, Jaeger-Krause M et al. · JCO precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer.

This study investigated how SCRMP-mediated SUMOylation of CSNK2B (casein kinase 2 beta) promotes DNA damage repair and cisplatin resistance in small cell lung cancer (SCLC) using multi-omic analyses of cisplatin-resistant patient-derived xenografts and the IMpower133 cohort. The key finding was that SCRMP-driven CSNK2B SUMOylation enhances DNA damage repair capacity, thereby facilitating platinum (cisplatin) resistance. This identifies a druggable post-translational modification axis (SCRMP–CSNK2B SUMOylation) that could be exploited to overcome platinum resistance in SCLC.

Chen Y, Chen Q, Guo J et al. · Science translational medicine · (2026) · View on PubMed ↗

RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.

This study investigated how the RNF43 p.G659fs (RNF43659fs) mutation drives immune dysfunction in microsatellite instability-high (MSI-H) colorectal cancer. Using single-cell RNA sequencing, multiplex immunohistochemistry, bulk RNA sequencing, and flow cytometry, the authors found increased NK cell infiltration but with inhibitory NK phenotypes, linked to PI3K/AKT/mTOR signaling and HLA-E up-regulation. These results connect a specific CRC mutation to an immunosuppressive NK-cell program, suggesting potential biomarkers and combination immunotherapy targets for MSI-H disease.

De Silva P, Fitzgerald S, Cazaubiel J et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.

The study examined how EGFR inhibition in EGFR-mutated lung cancer affects DNA repair of abortive topoisomerase I cleavage complexes (TOP1ccs) in drug-tolerant cells, focusing on TDP1 and reactive oxygen species. It found that EGFR inhibition transiently down-regulates TDP1, while elevated ROS promote TOP1 trapping, leading to persistent TOP1cc accumulation and adaptive resistance in drug-tolerant cells. These findings suggest that targeting the TDP1–TOP1cc axis could improve durability of EGFR-targeted therapies by preventing resistance arising from nonproliferative tolerant states.

Geraud M, Gence R, Casanova A et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Immunology & immune regulation (T cell exhaustion, allergy IgE memory, transplant tolerance, macrophage axes)

Fibroblasts restrain gut inflammation by IGF1-dependent regulation of innate lymphocytes.

This study examined how fibroblast subsets regulate intestinal immune responses by focusing on IGF1-expressing fibroblasts and their effects on group 3 innate lymphoid cells (ILC3s) in inflammatory bowel disease (IBD). It found that IGF1-expressing fibroblasts are reduced in IBD patients and that IGF1 stimulation limits ILC3 CXCL10 production and reduces recruitment of plasmacytoid dendritic cells (pDCs), thereby restraining gut inflammation in mouse models. The work supports a conserved fibroblast–ILC3–pDC regulatory axis as a therapeutic target to dampen chronic intestinal inflammation.

Lin Q, Liu RE, Wang Q et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.

This translational study investigated enterocolitis associated with BCMA CAR-T cell therapy (CAR-TEC) in multiple myeloma patients treated with ciltacabtagene autoleucel (cilta-cel) by profiling intestinal biopsies. Using single-cell transcriptomics, flow cytometry, and tissue imaging, the authors found persistent mucosal CAR-T cell presence alongside inflammatory remodeling, including depletion of mucosal B cells/plasma cells and expansion of specific inflammatory populations (as described in the truncated abstract). These findings clarify mucosal immune dynamics during cilta-cel toxicity and may inform biomarkers and management strategies for CAR-TEC.

Kethidi N, Pothukuchi S, Aleman A et al. · Nature medicine · (2026) · View on PubMed ↗

Targeting ZMYND8 unleashes IL-2 signalling to override T cell exhaustion.

The study examined how the chromatin reader ZMYND8 regulates IL-2 receptor (IL-2R)–STAT5 signaling and T cell exhaustion in the context of chronic viral infection and cancer. In vivo single-cell CRISPR screens identified ZMYND8 as an antagonist of IL-2R–STAT5 signaling that restrains effector-like differentiation, thereby promoting exhausted T cell states. This mechanistic insight suggests ZMYND8 as a potential immunotherapy target to restore IL-2 responsiveness and counter T cell exhaustion.

Wang Y, Shi H, Chapman NM et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

Lebrikizumab in Atopic Dermatitis: Associations of Patient Characteristics and Treatment History with Clinical Outcomes.

The study evaluated real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis (AD) across eight Italian university hospitals. In this multicenter observational cohort, outcomes including EASI75 at week 16 and additional clinical endpoints at weeks 16 and 24 were assessed in relation to patient characteristics and prior treatment history. The findings aim to identify which AD subgroups benefit most from lebrikizumab in routine care and to inform clinical decision-making beyond trial populations.

Gori N, Galluzzo M, Ippoliti E et al. · Dermatitis : contact, atopic, occupational, drug · (2026) · View on PubMed ↗

SPP1+ macrophage-induced CD74+ tumor cells promote adrenocortical carcinoma tumor thrombus via the SPP1/CD44/JAK/STAT signaling.

This study investigated how SPP1+ macrophages influence venous tumor thrombus formation in adrenocortical carcinoma (ACC) by focusing on CD74+ tumor cells, using integrated single-cell RNA sequencing and spatial transcriptomics from paired primary tumor and tumor thrombus (tail/head) samples from one ACC patient, followed by in vitro and in vivo validation. The authors found a distinct CD74+ tumor cell subcluster enriched in the VTT head region and showed that CD74 promotes ACC tumor thrombus through an SPP1/CD44/JAK/STAT signaling axis. These findings identify a macrophage–tumor cell signaling pathway (SPP1/CD44/JAK/STAT) that could be targeted to prevent or treat ACC-associated venous tumor thrombus.

Zhang H, Xu K, Zhen L et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Deletion of protein FSTL3 unravels the role of activin signaling in regulating macrophage L-arginine metabolism and kidney injury.

This study examined the role of the activin antagonist FSTL3 in regulating macrophage L-arginine metabolism and kidney injury by measuring serum FSTL3 in patients with chronic kidney disease (CKD) or acute kidney injury (AKI) and using mouse kidney injury models induced by folic acid or cisplatin. The key finding was that deletion of FSTL3 disrupts activin signaling and alters macrophage arginine metabolism, impacting injury outcomes in vivo. These results are significant because they link FSTL3/activin control of macrophage metabolic pathways to kidney injury and repair, suggesting a potential immunometabolic therapeutic axis.

Xing F, Xiang L, Yan J et al. · Kidney international · (2026) · View on PubMed ↗

Tezepelumab effectiveness in Aspirin-Exacerbated Respiratory Disease: a real-world multicenter study.

This multicenter retrospective real-world study evaluated the effectiveness of tezepelumab 210 mg every 4 weeks for 12 months in adults with severe uncontrolled asthma and aspirin-exacerbated respiratory disease (AERD), compared with severe asthma patients without AERD. Tezepelumab improved outcomes in routine practice and showed differential effectiveness versus non-AERD patients over follow-up. These findings support the clinical use of tezepelumab in AERD, a high-burden asthma phenotype, while informing expectations for response in real-world care.

Betancor D, Villalobos-Violan V, Antolin-Amerigo D et al. · Respiratory medicine · (2026) · View on PubMed ↗

EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.

This study investigated immune mechanisms of liver transplantation tolerance by integrating single-cell transcriptome/TCR profiling and flow cytometry with functional assays in 347 liver transplant recipients, supported by murine models and a prospective pediatric immunosuppressant withdrawal trial. It found that EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance. The results identify a specific tolerogenic T-cell population that could enable safer immunosuppression minimization after liver transplantation.

Liu Y, Wang B, Sun D et al. · Journal of hepatology · (2026) · View on PubMed ↗

Influence of newly initiated biologic therapy on the dose of ICS therapy - Data from the German Asthma Net.

This analysis of the German Asthma Net registry studied adults with severe asthma who initiated biologics (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, or tezepelumab) and assessed whether high-dose inhaled corticosteroids (HD-ICS) were reduced over 4 months to 2 years. The study found patterns of HD-ICS step-down after biologic initiation and evaluated associations with asthma control, exacerbations, lung function, and FeNO. These real-world data inform how clinicians can safely de-escalate ICS therapy after starting specific asthma biologics.

Stoshikj S, Renner A, Bal C et al. · The journal of allergy and clinical immunology. In practice · (2026) · View on PubMed ↗

Germinal center interleukin-4 microniches drive tissue divergence of IgE memory B cell responses.

The study examined how germinal center (GC) interleukin-4 (IL-4) microniches regulate IgE memory B cell (MBC) reactivation in mouse models of airborne house dust mite and Alternaria exposure. It found two MBC differentiation trajectories on allergen re-exposure—an IL-4-rich GC-dependent pathway producing IgG1+ and IgE+ plasma cells mainly in lymph nodes (LNs), and a GC-independent pathway producing mainly IgG1+ plasma cells present in both LNs and lungs. This mechanistic insight links tissue-specific IL-4 GC microenvironments to IgE recall responses, informing strategies to prevent or reprogram allergic IgE memory.

Villazala-Merino S, Bertoia L, Fenouil R et al. · Immunity · (2026) · View on PubMed ↗

Clinical Uses of Common Genetic Variants Associated with Common Diseases.

This narrative review examined how common genetic variants identified by genome-wide association studies (GWAS) are used clinically, particularly through polygenic risk scores (PRS), across common adult-onset diseases. It emphasizes that although thousands of small-effect variants predict risk in aggregate, PRS have had limited impact on routine diagnosis and treatment for most common conditions. The significance is that it frames the translational gap between genomic risk prediction and actionable clinical benefit, guiding future implementation strategies.

Hunter DJ, Inouye M · The New England journal of medicine · (2026) · View on PubMed ↗

Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.

This prospective, multicenter real-world study compared first-line infliximab versus vedolizumab effectiveness in biologic-naïve patients with moderate-to-severe ulcerative colitis using inverse probability of treatment weighting. The primary composite endpoint was 14-week clinical remission plus 52-week endoscopic remission, with secondary outcomes including clinical and endoscopic response/remission. The findings provide comparative effectiveness evidence to guide biologic selection in routine care for ulcerative colitis patients.

He D, Sha S, Liu X et al. · Inflammatory bowel diseases · (2026) · View on PubMed ↗

The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis.

This study tested the nucleoside analog kamuvudine-9 (K-9) in the experimental autoimmune encephalitis mouse model of multiple sclerosis, building on prior evidence that NRTIs and kamuvudines inhibit inflammasome activation. K-9 prevented further neurological deficits and reversed preexisting paralysis and vision loss, promoting myelin and axonal preservation and abolishing inflammasome-driven pathology. The findings support K-9 as a potentially safer NRTI-derivative strategy to therapeutically target inflammasome activation in MS.

Yerramothu P, Ambati K, Magagnoli J et al. · Science translational medicine · (2026) · View on PubMed ↗

Mechanism of GPR84 allosteric modulation at a helix 8-proximate site.

This study examined the mechanism of allosteric modulation of the immune-metabolic GPCR GPR84 at a helix 8-proximate site. Using cryo-electron microscopy of GPR84–Gi complexes bound to the orthosteric agonist OX04539 with or without the positive allosteric modulator PSB-16671, along with molecular dynamics and mutagenesis, the authors identified a PSB-16671 allosteric site formed between TM1 and TM7 that enables Gi-biased signaling. These structural and mechanistic insights can guide the rational design of pathway-selective GPR84 modulators.

Zhang X, Guseinov AA, Jenkins L et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

PRMT1-mediated methylation controls OFIP ubiquitination and centrosome duplication to maintain epidermal homeostasis.

The study examined how PRMT1-mediated arginine methylation regulates OFIP ubiquitination and centrosome duplication to maintain epidermal homeostasis in mice. It found that Prmt1 ablation causes epidermal hyperplasia with basal layer expansion and mitotic fidelity defects, and mechanistically that PRMT1 directly catalyzes asymmetric arginine dimethylation of a centrosome-associated substrate (OFIP) that controls OFIP ubiquitination and proper centrosome duplication. These results connect PRMT1-dependent post-translational control to genome stability and tissue homeostasis, suggesting PRMT1 as a candidate target in disorders involving epidermal dysregulation.

Liu K, Song T, Zhao J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

---

Metabolic disease & liver health (MASLD, renal/metabolic kidney outcomes, uric acid, hyperuricemia)

Transition to once-weekly growth hormone in paediatric isolated growth hormone deficiency: A real-world experience.

This real-world retrospective study evaluated pediatric patients with isolated growth hormone deficiency (GHD) who transitioned from daily recombinant human growth hormone to once-weekly somatrogon, tracking auxological and biochemical outcomes. The key finding was the change in height standard deviation score (SDS) and height velocity SDS over 6, 12, and 18 months after transition (full results truncated in the provided abstract). These data inform how somatrogon performs outside clinical trials and can guide dosing/monitoring decisions for children with isolated GHD.

Sotiriou G, Moutafi M, Triantafyllou P et al. · European journal of endocrinology · (2026) · View on PubMed ↗

Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation.

This target trial emulation study compared renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors versus GLP-1 receptor agonists, using linked electronic health records and claims data from 10 health systems and two national insurance plans in the BESTMED study. The key finding was the relative risk of renal deterioration under each drug class stratified by baseline albuminuria status (albumin-to-creatinine ratio ≥30 mg/g), with results derived from emulated comparative effectiveness rather than randomized assignment. Clinically, the study informs which second-line glucose-lowering therapy may better preserve kidney function in type 2 diabetes patients at different albuminuria risk levels.

Turchin A, Petito LC, Hegermiller E et al. · BMJ (Clinical research ed.) · (2026) · View on PubMed ↗ · Free PDF ↗

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.

This Phase 2 randomized, double-blind, placebo-controlled crossover trial evaluated lorundrostat, a selective aldosterone synthase inhibitor, in adults with uncontrolled hypertension, chronic kidney disease, and albuminuria who were already receiving an SGLT2 inhibitor. The key finding was the effect of adding lorundrostat (25 mg/day) on clinical and biomarker endpoints related to kidney disease progression and albuminuria under these comorbid conditions. Clinically, the trial tests whether aldosterone blockade via lorundrostat provides incremental renal benefit in a high-risk CKD population with persistent albuminuria.

Weir MR, Bhaduri S, Lee K et al. · Kidney international · (2026) · View on PubMed ↗

Novel human neutralizing monoclonal antibodies against Pregnancy-Associated Plasma Protein A for the treatment of Autosomal Dominant Polycystic Kidney Disease.

This preclinical study developed novel human neutralizing monoclonal antibodies (pan-selective PAPPA-mAbs) against pregnancy-associated plasma protein A (PAPPA) and tested their efficacy in mouse models of autosomal dominant polycystic kidney disease (ADPKD). The key finding was that the generated antibodies neutralize PAPPA-mediated cleavage of IGF binding proteins (IGFBP2, IGFBP4, IGFBP5) in human epithelial cells and improved disease phenotypes in early and advanced polycystic kidney disease models across multiple doses. Scientifically and therapeutically, the work advances human PAPPA-targeting antibody candidates that could suppress PAPPA-driven IGF signaling in ADPKD.

Hu E, Gardener MJ, Wang X et al. · Kidney international · (2026) · View on PubMed ↗ · Free PDF ↗

The osteogenic regulator THOC5-dependent post-transcriptional control maintains vascular smooth muscle cell homeostasis against chronic kidney disease related vascular calcification.

This study investigated how THOC5-dependent post-transcriptional regulation maintains vascular smooth muscle cell (VSMC) homeostasis against chronic kidney disease (CKD)-associated vascular calcification, using patient arterial tissues and mouse models plus in vitro and in vivo VSMC calcification systems. The key finding was that THOC5 is required to prevent osteogenic transdifferentiation of VSMCs during CKD-related vascular calcification, with THOC5-dependent mechanisms identified as protective. The results are significant because they pinpoint THOC5 as a potential molecular target to reduce CKD-driven vascular calcification and its cardiovascular complications.

Cheng A, Wang Y, Liu Y et al. · Kidney international · (2026) · View on PubMed ↗

Toward International Dietary Guidance: A Food Guide Pyramid for Human and Planetary Health.

This work developed an evidence-informed International Food Guide Pyramid for human and planetary health, emphasizing optimal carbohydrate-containing staple foods, using a four-step evidence-review process comparing major national/regional dietary guideline systems. The key output was a globally relevant dietary guidance framework aligned with both health outcomes and environmental considerations. Scientifically and policy-wise, it provides a structured basis for harmonizing future dietary recommendations worldwide.

Della Corte KA, Buyken AE, La Vecchia C et al. · Advances in nutrition (Bethesda, Md.) · (2026) · View on PubMed ↗ · Free PDF ↗

MASLD: Established Knowledge and Emerging Directions - Guideline Updates.

This article reviewed established knowledge and emerging directions for metabolic dysfunction-associated steatotic liver disease (MASLD), including guideline updates across the disease spectrum from steatosis to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. It highlights that lifestyle modification remains foundational while pharmacologic therapy is increasingly emphasized for patients with progressive disease or high-risk profiles. Clinically, the synthesis supports more standardized risk stratification and treatment selection to reduce progression to cirrhosis, hepatocellular carcinoma, and cardiovascular complications.

Roeb E, Geier A · Zeitschrift fur Gastroenterologie · (2026) · View on PubMed ↗

The guanine nucleotide exchange factor Rin-like is a repressor for renal uric acid excretion in human and mouse.

This work studied the guanine nucleotide exchange factor Rin-like (RINL; RAS and RAB interactor-like) as a regulator of renal uric acid (UA) excretion in human genetics and mouse models. The human hRINL Pro139→Ser (P139S) mutation was identified as pathogenic for familial hyperuricemia, and RINL activated RAB5C in renal tubular epithelial cells to promote UA endocytosis and lysosomal degradation. These mechanistic and genetic findings implicate the RINL–RAB5C pathway as a potential therapeutic target for hyperuricemia and gout.

Han C, He C, Hu W et al. · Science translational medicine · (2026) · View on PubMed ↗

---

mTOR/nutrient–translation & aging/geroscience (lifespan, translation control, TSC astrocytes)

The Role of EVs in the Aging Hematopoietic System.

This review examined how extracellular vesicles (EVs) regulate signaling within the aging hematopoietic system, focusing on interactions between bone marrow niche cells and hematopoietic stem and progenitor cells (HSPCs). It reports that aging-driven senescence and telomere attrition remodel EV biogenesis and cargo, with aged EVs—especially from senescent mesenchymal stromal cells and osteoblasts—showing altered microRNA profiles and reduced protective antioxidants that contribute to niche dysfunction. These insights highlight EV cargo as a potential mechanistic driver and therapeutic target for restoring healthy hematopoiesis during aging.

Kosebent EG, Havranek N, Kollmann K et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila.

The study examined how the protein Lsp2 connects mTORC1 signaling to translation of 5’-terminal oligopyrimidine (TOP) motif mRNAs and to lifespan regulation in Drosophila. Lsp2 was found to link mTORC1 activity to TOP mRNA translation control in a way that is resistant to rapamycin, thereby tuning ribosomal protein synthesis and affecting aging. This mechanistic pathway provides a new targetable node for understanding and potentially modulating nutrient–translation coupling to influence lifespan.

Wang J, Cai Z, Gu J et al. · Nature · (2026) · 2 citations · View on PubMed ↗

Lsp2 links early-life diet to adult translation and lifespan in Drosophila.

The study investigated whether early-life protein restriction (ePR) in Drosophila alters adult translation programs and lifespan, using stable-isotope tracing to track dietary amino acids into adulthood. Early-life protein restriction extended adult lifespan by lowering storage protein levels and by retaining larval-stage amino acids into early adulthood where they were incorporated into ribosomal components, shifting translation capacity. These results connect juvenile diet to adult translational remodeling as a causal mechanism for lifespan extension.

Kosakamoto H, Okada R, Barker CS et al. · Nature · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience.

The article proposed a geroscience framework arguing that aging is best understood as progressive loss of biological self-correction rather than only accumulation of damage. It synthesizes the idea that aging reflects impaired capacity to sense perturbations, scale responses, repair or remove damage, terminate responses, and re-equilibrate while preserving future functional reserve. This conceptual model aims to guide interventions toward restoring resilience and healthspan, potentially informing strategies to address inflammaging and longevity.

Bar-Or D, Williams J, Paredes D · Geriatrics (Basel, Switzerland) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular prevention & real-world comparative effectiveness (GLP-1/dual agonists, LAAO vs DOAC, semaglutide mediators, valve adoption, multimorbidity biomarkers)

Triglyceride-glucose waist-to-height ratio in relation to prevalent and incident multimorbidity: cross-sectional and prospective evidence from four national studies.

This cross-sectional and prospective study analyzed adults aged ≥50 years from multiple national cohorts (NHANES, HRS, CHARLS, and ELSA) to test whether the triglyceride-glucose waist-to-height ratio (TyG-WHtR) predicts prevalent and incident multimorbidity and to identify dose-response thresholds. The study found TyG-WHtR was associated with multimorbidity outcomes across populations, supporting its role as an integrated marker of insulin resistance and central adiposity. Clinically, TyG-WHtR could improve risk stratification for multimorbidity in older adults and guide early metabolic intervention.

Shao Z, Hu H, Ge X et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.

The study compared stroke outcomes associated with tirzepatide versus GLP-1 receptor agonists in adults with atrial fibrillation and type 2 diabetes using a retrospective cohort from a large federated electronic health-record network. Across 14,118 matched pairs, tirzepatide initiation was associated with lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and all-cause death compared with other GLP-1 receptor agonists. These real-world findings suggest tirzepatide may reduce cerebrovascular risk in this high-stroke-risk population, supporting further prospective evaluation.

Lin CL, Lin KC, Yu JM et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials.

This individual participant data (IPD) network meta-regression of double-blind randomized trials studied how specific antidepressants versus placebo affect heart-rate corrected QT interval (QTc) during the first 8 weeks in adults with major depressive disorder and whether antidepressant use relates to early major adverse cardiovascular events (MACE). The key finding was the comparative QTc changes by antidepressant and the associated early MACE signal assessed across trials. Scientifically and clinically, the work helps rank antidepressants by early cardiac electrophysiology risk and clarifies whether QTc effects translate into early cardiovascular harm.

Ostinelli EG, Capocci S, Li Z et al. · BMJ (Clinical research ed.) · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.

This mediation analysis studied which changes from randomization to 24 months explain the cardiovascular benefit of subcutaneous semaglutide 2.4 mg weekly in adults with pre-existing cardiovascular disease and BMI ≥27 kg/m2 without diabetes in the SELECT trial. The analysis evaluated candidate mediators including body weight, waist circumference, hsCRP, HbA1c, lipids, blood pressure, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio, individually and in combination, to determine their contribution to reduced major adverse cardiovascular events (MACE). Scientifically, it clarifies the pathways through which semaglutide lowers MACE, which can refine risk-targeted use and mechanistic understanding of GLP-1–based prevention.

Colhoun HM, Lincoff AM, Ryan D et al. · European heart journal · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Temporal Trends in Transcatheter Tricuspid Valve Interventions After FDA Approval in the United States.

This retrospective cohort study assessed temporal trends in transcatheter tricuspid valve interventions (TTVIs) after FDA approval in the United States, focusing on transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR). Using the Vizient Clinical Data Base, it characterized monthly procedural adoption from October 2024 to December 2025 and described baseline patient characteristics and in-hospital outcomes. The findings are significant for understanding real-world uptake and early safety/effectiveness patterns of newly approved TTVI technologies.

Rawlley B, Reisinger M, Murphy HR et al. · JACC. Advances · (2026) · View on PubMed ↗ · Free PDF ↗

Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation: Network Meta-Analyses.

This study performed network meta-analyses of randomized controlled trials to compare left atrial appendage occlusion (LAAO) versus direct oral anticoagulants (DOACs) for atrial fibrillation. It evaluated efficacy using a composite of stroke, systemic embolism, and cardiovascular death and safety using major bleeding, synthesizing evidence across trials via two network meta-analyses. Clinically, the results aim to determine whether LAAO provides superior or comparable stroke prevention and bleeding risk relative to DOAC therapy.

Hiruma Y, Aikawa T, Kawamura I et al. · JACC. Advances · (2026) · View on PubMed ↗ · Free PDF ↗

Metabolomic profiling of ultra-processed food consumption and cardiovascular risk in Spanish preschool children: a cross-sectional study.

This cross-sectional study investigated associations between ultra-processed food (UPF) consumption and cardiovascular risk using plasma metabolomic profiling in Spanish preschool children aged 3–6 years from the CORALS cohort. It aimed to identify metabolomic signatures linked to UPF intake and test their relationship with cardiovascular risk factors in 1148 children recruited across seven Spanish cities. The scientific significance is that metabolite patterns may provide early biomarkers connecting UPF exposure to childhood cardiovascular alterations.

Pérez-Acosta JA, García-Gavilán JF, Margara-Escudero HJ et al. · EBioMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

The study integrated results from the TETON-1 and TETON-2 phase 3 double-blind trials to evaluate the efficacy of inhaled treprostinil versus placebo in patients with idiopathic pulmonary fibrosis (IPF). It analyzed changes in absolute forced vital capacity (FVC) at week 52 and multiple secondary endpoints including time to clinical worsening, exacerbations, survival, quality of life, and lung function measures. The combined analysis is intended to provide more precise and robust estimates of treprostinil’s clinical benefit for IPF patients.

Nathan SD, Smith P, Deng C et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer risk prediction & prevention (BRCA/ovarian, lifestyle in PMOS)

Diagnosis and management of Silver-Russell syndrome: second international consensus statement.

This second international consensus statement used a Delphi-like process to update diagnosis and management guidance for Silver-Russell syndrome (SRS), emphasizing molecular criteria in a genetically heterogeneous population. It highlights that diagnosis should be primarily based on strict molecular findings, particularly maternal uniparental disomy for chromosome 7 (upd(7)mat) and/or loss of methylation at the H19/IGF2 imprinting control region (IG-DMR) on 11p15. Clinically, the updated recommendations standardize molecular diagnosis and management, improving consistency of care and enabling earlier, more accurate identification of affected individuals.

Wakeling E, Davies JH, Giabicani E et al. · Nature reviews. Endocrinology · (2026) · View on PubMed ↗ · Free PDF ↗

Near pan-alphavirus neutralization by an antibody-nanobody bispecific.

The study investigated a bispecific antibody–nanobody construct designed to achieve near pan-alphavirus neutralization across multiple human-infecting alphaviruses. The key finding was that the bispecific format enabled broad neutralizing activity with sufficient potency against each targeted alphavirus to support cross-protection potential. This supports the development of a single stockpiled therapeutic strategy against emerging alphavirus threats.

Pletnev S, Gardner CL, Sutton MS et al. · mAbs · (2026) · View on PubMed ↗ · Free PDF ↗

Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study.

This nationwide nested case-control study in Danish registries evaluated whether current menopausal hormone therapy is associated with venous thromboembolism, ischaemic stroke, and myocardial infarction in women aged 50–69 years. The key finding was the magnitude and direction of thrombotic and cardiovascular risks associated with current hormone therapy use compared with non-use, quantified across the identified case groups (VTE, stroke, MI). The results are clinically significant for risk stratification and safer selection of menopausal hormone therapy to reduce thrombotic and cardiovascular events.

Berggreen J, Pourhadi N, Wood-Kurland H et al. · BMJ (Clinical research ed.) · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

The effect of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome: A systematic review and meta-analysis.

The study systematically reviewed and meta-analyzed clinical trials of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome (PMOS), comparing lifestyle approaches versus minimal/no treatment (usual care) across reproductive, anthropometric, and metabolic outcomes. It found pooled effects (via random-effects meta-analysis) that quantify how lifestyle interventions change key PMOS outcomes, with subgroup analyses to evaluate differential effectiveness across outcome domains. Clinically, the results support evidence-based recommendations for lifestyle management in PMOS and help clarify which outcome areas are most likely to improve.

Olalere O, Koh MD, Crabb K et al. · PLoS medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers.

This prospective international cohort study modeled residual lifetime ovarian cancer risk in women carrying BRCA1 or BRCA2 variants, comparing current age with projected age at bilateral salpingo-oophorectomy (BSO) and considering delays until menopause. The study estimated how much ovarian cancer risk remains when BSO is performed later than guideline ages (35 years for BRCA1 and 45 years for BRCA2), quantifying residual risk by age. These projections can support individualized counseling on the timing of risk-reducing surgery for BRCA1/2 carriers when patients consider delaying BSO.

Giannakeas V, Apostol AI, Diella C et al. · JAMA surgery · (2026) · View on PubMed ↗

Management of Colon and Rectal Injuries From Blunt and Penetrating Trauma: Evidence-Based Recommendations From the World Society of Emergency Surgery.

This World Society of Emergency Surgery evidence-based guideline development effort synthesized data to address diagnosis, operative strategy, technical conduct, and perioperative management of adult colon and rectal injuries from blunt and penetrating trauma. The recommendations reflect current practice trends such as selective primary repair and physiology-guided reconstruction rather than routine mandatory fecal diversion. These guidance statements aim to reduce variability and improve outcomes in the surgical management of traumatic colorectal injuries.

Ribeiro MAF, Efron DT, Dattwyler MP et al. · JAMA surgery · (2026) · View on PubMed ↗

---

Infectious disease & antiviral/vaccine/antimicrobial development (alphaviruses, malaria structure/transmission, ASFV, Leishmania, TB delivery, outbreak risk)

Reference genomes and fossils revise bat family phylogeny and biogeography.

The study analyzed bat evolution by generating and comparing chromosome-level, long-read reference genomes from 103 bat species spanning all 21 bat families, including 42 new assemblies. The resulting phylogenomic analysis revised bat family relationships and biogeography, placing Myzopodidae as the earliest branch within Vespertilionoidea and identifying Emballonuroidea and Vespertilionoidea as sister groups. This improved genomic framework clarifies the evolutionary history underlying key bat traits such as flight and echolocation and refines how these lineages dispersed over time.

Morales AE, Liang Y, Thomas WR et al. · Nature · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

The anthropogenic fingerprint on emerging infectious diseases.

The study assessed how anthropogenic drivers shape geographic outbreak risk for emerging infectious diseases by analyzing 58,319 outbreak event records across 32 diseases. Using statistical modeling that accounts for detection and reporting biases, the authors found highest outbreak risks in mosaic landscapes where people and livestock coexist with forests and fragmented ecosystems. These results quantify how human land-use patterns influence emergence risk, informing surveillance and risk-reduction strategies.

Gibb R, Ryan SJ, Pigott DM et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

A methanogen hydrolase reveals the structure of archaeal peptidoglycan.

The study characterized an archaeal peptidoglycan (archaeal PG/pseudomurein) hydrolase by identifying ArmA from Methanobrevibacter smithii. The authors used ArmA-mediated digestion to reveal an unexpected architecture of archaeal PG and established ArmA as the first glycosyl hydrolase specific for archaeal PG. This advances analytical tools for archaeal cell-wall biology and refines antimicrobial target concepts involving archaeal PG-like polymers.

Smith R, Pende N, Rifflet A et al. · Nature · (2026) · View on PubMed ↗

Sailing to a deeper understanding of malaria parasite invasion.

This article reviewed recent atomic-level structural findings on the malaria parasite red blood cell invasion protein complex and discussed implications for next-generation antimalarial drug development. The key takeaway was that structural resolution of the invasion machinery clarifies how the complex mediates entry, enabling more rational targeting strategies. This review frames how structure-guided design could accelerate development of invasion-blocking therapeutics for malaria.

Tobin AB · Trends in parasitology · (2026) · View on PubMed ↗ · Free PDF ↗

Direct cell-to-cell transmission of retrotransposons.

This Cell study investigated whether certain LTR retrotransposons can spread between cells by infecting the germline from somatic cells in the Drosophila ovary. It identified a retrotransposon-encoded short transmembrane protein, sORF2, that localizes to invasive somatic protrusions and enables retrotransposon transmission without the fusogenic Envelope protein typical of retroviral entry. The work expands understanding of how mobile genetic elements can achieve cell-to-cell spread and germline infection using non-canonical mechanisms.

Voichek M, Bernhard A, Lauterjung L et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Transmembrane delivery of antimicrobial peptides by engineered eCIS into macrophages for intracellular mycobacteria elimination.

This study engineered the bacterial extracellular Contractile Injection System (eCIS) using the Photorhabdus virulence cassette (PVC) to deliver antimicrobial peptides into macrophages for intracellular mycobacteria killing. The engineered eCIS (eCIS/PVC) enabled transmembrane delivery of AMPs and significantly inhibited survival of intracellular Mycobacterium smegmatis, Mycobacterium bovis, Mycobacterium tuberculosis, and an isoniazid-resistant M. tuberculosis strain. The approach provides a potential platform to improve intracellular targeting and treatment accuracy against drug-resistant tuberculosis.

Wu Q, Zhang R, Yan MY et al. · Science advances · (2026) · View on PubMed ↗ · Free PDF ↗

Transcriptional architecture of African swine fever virus.

The study characterized the transcriptional architecture of African swine fever virus (ASFV) using nanopore sequencing to map viral transcription start/termination sites and to detect RNA species in the context of ASFV’s host-independent transcription system. It found that direct RNA sequencing plus experimental validation supports long multicistronic RNAs and enabled identification of six novel transcriptional genes, along with observation of transcriptional read-through events. These results refine ASFV genome annotation and reveal new candidate viral genes that could be targeted for antiviral or transmission-blocking strategies.

Wang G, Li P, He X et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

The translatome of quiescent Plasmodium falciparum gametocytes reveals parasite pyridoxal 5’-phosphate (PLP) biosynthesis is essential for efficient mosquito stage development.

The study analyzed the translatome of quiescent Plasmodium falciparum stage V gametocytes to determine which metabolic pathways are required for efficient mosquito-stage development, focusing on pyridoxal 5’-phosphate (PLP) biosynthesis. Using L-azidohomoalanine incorporation into nascent proteins (click chemistry-based labeling) to profile translation, it found that PLP biosynthesis is essential for efficient progression through the mosquito stage. This identifies PLP biosynthesis as a potential vulnerability for transmission-blocking interventions against malaria.

Alves E, Houghton JW, Stewart LB et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

Substitutions affecting the HA-NA-receptor balance preceded the emergence of the pandemic 2009 H1N1 virus.

The study investigated whether changes in hemagglutinin–neuraminidase (HA–NA) receptor balance in swine influenza A viruses preceded the emergence of the 2009 pandemic H1N1 virus. Using phylogenetic analysis of (pre)pandemic swine viruses collected in Mexico after H1N1pdm09 emergence, it found evidence that HA–NA balance substitutions emerged prior to the pandemic emergence, consistent with adaptation to differences in host sialoglycomes. This highlights HA–NA balance as a potential early marker for identifying swine viruses with pandemic potential.

Marougka K, Leiva-Rebollo R, Hofma F et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

---

Ophthalmology (retinal vascular disease, diabetic retinopathy, ocular safety in asthma biologics)

Efficacy and safety of intravitreal conbercept injection in treating macular oedema secondary to branch retinal vein occlusion: results from the BRAVE study.

The BRAVE study investigated intravitreal conbercept versus a control regimen for macular edema secondary to branch retinal vein occlusion (BRVO-ME) in 255 randomized patients. Conbercept produced a significantly greater improvement in best-corrected visual acuity (BCVA) letter score at 6 months than control, with efficacy assessed as the primary endpoint and safety monitored through the study period. These results support conbercept as an effective intravitreal treatment option for BRVO-associated macular edema.

Wei W, Shi X, Li X et al. · The British journal of ophthalmology · (2026) · View on PubMed ↗ · Free PDF ↗

Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma.

This retrospective target trial emulation study used the TriNetX US Collaborative Network (2018–2025) to compare ocular adverse event risk in adults with asthma initiating dupilumab versus IL-5 inhibitors (mepolizumab or benralizumab). Dupilumab showed a different (comparative) ocular safety profile relative to IL-5 inhibitors, with risk estimates derived from real-world treatment initiation cohorts. Clinically, the findings help guide biologic selection for asthma patients concerned about ocular adverse events.

Tsao HM, Wu PL, Wang YH et al. · The journal of allergy and clinical immunology. In practice · (2026) · View on PubMed ↗

Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy.

This study evaluated the orally available peptide drug danegaptide for nonproliferative diabetic retinopathy (NPDR) using preclinical models and clinical assessment. Danegaptide was found to regulate retinal vascular permeability and reduce disease-relevant retinal pathology compared with controls, supporting systemic delivery as an alternative to frequent intravitreal VEGF-neutralizing injections. These results suggest danegaptide could improve treatment adoption and reduce injection burden while maintaining efficacy for NPDR.

Hudson N, Porkoláb G, O’Callaghan J et al. · Science translational medicine · (2026) · View on PubMed ↗

---

Stroke therapeutics & thrombosis management (thrombolysis/EVT, anticoagulation intensity)

Pre-hospital time and risk of perforation in patients with acute appendicitis in 112 countries (AlliGatOr): an international, prospective, observational cohort study.

This international prospective observational cohort study (AlliGatOr) examined whether pre-hospital time (symptom onset to first surgical assessment) is associated with perforation risk in patients undergoing emergency appendicectomy for suspected acute appendicitis across 1377 hospitals in 112 countries. It quantified the relationship between delayed presentation and perforation outcomes using contemporary global data. The findings can reduce unnecessary negative appendicectomies while improving triage and timing of surgical care worldwide.

Anyomih TTK, Aregawi AB, Calvache JA et al. · The Lancet. Global health · (2027) · View on PubMed ↗ · Free PDF ↗

Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial.

In this multicenter, open-label, blinded-endpoint randomized clinical trial in China, patients with moderate-to-severe basilar artery occlusion presenting 4.5 to 24 hours after stroke onset were assigned to intravenous tenecteplase before endovascular thrombectomy (EVT) versus EVT alone. Tenecteplase given prior to EVT improved clinical outcomes compared with EVT alone while assessing safety in this extended time window. If confirmed, this strategy could expand the effective treatment window for basilar artery occlusion by adding IV tenecteplase to EVT for selected patients.

Li R, Yao X, Nogueira RG et al. · JAMA · (2026) · View on PubMed ↗

---

Iron deficiency anemia in pregnancy (IV vs oral)

Intravenous vs Oral Iron for Treating Iron Deficiency Anemia in Pregnancy: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis of randomized clinical trials compared intravenous (IV) versus oral iron for treating iron deficiency anemia (IDA) during pregnancy and evaluated maternal and neonatal outcomes. The analysis synthesized evidence on whether IV iron provides better hematologic and pregnancy-related outcomes than oral iron. The findings inform clinical guideline decisions on the optimal iron route in pregnancy to improve maternal and neonatal health.

Sales SK, Rajprohat S, Simon L et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

---

COVID-19 therapeutics & anticoagulation strategies

Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.

In the HERO-19 randomized clinical trial conducted in Germany, hospitalized patients with confirmed COVID-19 were assigned to therapeutic anticoagulation plus standard of care versus prophylactic anticoagulation plus standard of care. The trial evaluated whether therapeutic anticoagulation improved objective, patient-relevant outcomes compared with prophylactic dosing. Results directly guide anticoagulation intensity decisions for hospitalized COVID-19 patients in ICU and non-ICU settings.

Karakas M, Nicolay SS, Wichmann D et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on September 25, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.